Αρχική World News Postneoadjuvant Trastuzumab Deruxtecan Results in Higher Likelihood of iDFS Among Patients with... World News Postneoadjuvant Trastuzumab Deruxtecan Results in Higher Likelihood of iDFS Among Patients with HER2-positive EBC with Residual Invasive Disease After Neoadjuvant Treatment Από Ogkologos - 12 Δεκεμβρίου, 2025 562 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the interim analysis of the DESTINY-Breast05 study Source ΠΑΡΟΜΟΙΑ ΑΡΘΡΑΠΕΡΙΣΣΟΤΕΡΑ ΑΠΟ ΤΟΝ ΔΗΜΙΟΥΡΓΟ Ahead of the Special European Council Meeting on 26-27 November, ESMO Calls on EU Governments to Continue Support for the Cancer Mission European Parliament backs key priorities advocated by ESMO for cancer research and innovation FDA approves giredestrant in combination with everolimus for ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer MOST POPULAR National Study Examines Genetic Testing to Inform Follow-up Care for Cancer... 7 Μαΐου, 2026 Fourth Vaccine Dose Increases in Humoral Immunity Against Omicron Variants in... 3 Οκτωβρίου, 2022 No Improvement in OS or PFS from Sacituzumab Govitecan Compared with... 24 Μαρτίου, 2025 Doctors Think Woman Has A Brain Tumor, But Then They Open... 17 Ιουνίου, 2019 Φόρτωση περισσοτέρων HOT NEWS Welcome to Caring Connections Reflections from our chief scientist: The rise of the whole organism Working to Make Cancer Clinical Trials More Inclusive: A Q&A With... The Combination of Nivolumab and Cabozantinib Provides a New First-Line Treatment...